scholarly journals The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study

2011 ◽  
Vol 14 (4) ◽  
pp. 302-306 ◽  
Author(s):  
O Haillot ◽  
A Fraga ◽  
P Maciukiewicz ◽  
D Pushkar ◽  
T Tammela ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Clinical Outcomes ◽  
Post Hoc Analysis ◽  
Post Hoc

Clinical outcomes of TAVI or SAVR in men and women with aortic stenosis at intermediate operative risk: a post hoc analysis of the randomised SURTAVI trial

2020 ◽  
Vol 16 (10) ◽  
pp. 833-841
Author(s):  
Nicolas M. Van Mieghem ◽  
Michael J. Reardon ◽  
Steven J. Yakubov ◽  
John Heiser ◽  
William Merhi ◽  
...  
Keyword(s):  
Aortic Stenosis ◽  
Clinical Outcomes ◽  
Operative Risk ◽  
Men And Women ◽  
Post Hoc Analysis ◽  
Post Hoc

Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory post-hoc analysis of COU-AA-302 trial data.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e16529-e16529
Author(s):  
Dominic Pilon ◽  
Ajay S. Behl ◽  
Rhiannon Kamstra, ◽  
Yongling Xiao ◽  
Marie-Helene Lafeuille ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Gleason Score ◽  
Group Performance ◽  
Trial Data ◽  
Cox Models ◽  
Post Hoc Analysis ◽  
Opiate Use ◽  
Psa Progression ◽  
Ecog Ps ◽  
Post Hoc

e16529 Background: A post-hoc analysis of COU-AA-302 trial data showed that brief pain inventory (BPI), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and bone metastases were predictors for overall survival in men with mCRPC treated with AA+P. This study aimed to identify baseline predictors of other clinical outcomes. Methods: COU-AA-302 trial data were used to develop predictive models for prostate-specific antigen (PSA) progression, Eastern Cooperative Oncology Group performance status (ECOG PS) deterioration, and opiate use. Associations between baseline factors and outcomes were first assessed using multivariable Cox models among AA+P patients (Step 1). In Step 2, interaction testing was conducted between treatment (AA+P vs. placebo) and each potential predictor (P < 0.2) identified in Step 1. Final Cox models included predictors and any significant interactions (p < 0.05). Results: A total of 1,034 men (525 AA+P; 509 placebo) were included in the analysis. Baseline BPI, PSA, LDH, and ALP were predictors of PSA progression and opiate use regardless of AA+P or placebo with higher values indicating higher risks (all P < 0.05). Younger age, shorter time from luteinizing hormone-releasing hormone to randomization, higher Gleason score, and lower PSA at diagnosis were also associated with higher risks of opiate use: (all P < 0.05). For ECOG PS deterioration, higher baseline BPI, PSA, LDH, and Gleason score, older age, and lower baseline ECOG were associated with higher risks regardless of AA+P or placebo (all P < 0.05). Baseline ALP and site of metastasis also predicted ECOG PS deterioration but the effect varied by treatment (lower risk in AA+P versus placebo; both interactions’ P < 0.05). Conclusions: Predictors of PSA progression, ECOG PS deterioration, and opiate use were identified in AA+P and placebo-treated men with mCRPC. No predictors were associated with worse outcomes for AA+P versus placebo, while the negative impact of certain predictors on ECOG PS was favorably modified by AA+P. Further study is needed on the relationship between AA+P and prognostic factors.

scholarly journals Clinical outcomes after joint surgery in patients on turoctocog alfa pegol (N8‐GP) prophylaxis: A post hoc analysis

Haemophilia ◽  
2021 ◽  
Author(s):  
Kingsley Hampton ◽  
Andreas Tiede ◽  
Shwetha Shivamurthy ◽  
Pratima Chowdary
Keyword(s):  
Clinical Outcomes ◽  
Post Hoc Analysis ◽  
Joint Surgery ◽  
Post Hoc

Certolizumab Pegol Plasma Concentrations and Endoscopic and Clinical Outcomes in Crohnʼs Disease: A Post Hoc Analysis of the MUSIC Trial: Presidential Poster

2012 ◽  
Vol 107 ◽  
pp. S674-S675 ◽  
Author(s):  
William Sandborn ◽  
Jean-Frederic Colombel ◽  
Matthieu Allez ◽  
Jean-Louis Dupas ◽  
Olivier Dewit ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Certolizumab Pegol ◽  
Plasma Concentrations ◽  
Post Hoc Analysis ◽  
Post Hoc

Clinical outcomes after switching to migalastat from agalsidase alfa or agalsidase beta in patients with Fabry disease: Post hoc analysis from ATTRACT

2019 ◽  
Vol 126 (2) ◽  
pp. S141
Author(s):  
Gere Sunder-Plassmann ◽  
Ana Jovanovic ◽  
Ulla Feldt-Rasmussen ◽  
Vipul Jain ◽  
Markus Peceny ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Clinical Outcomes ◽  
Agalsidase Beta ◽  
Post Hoc Analysis ◽  
Agalsidase Alfa ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document